Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACELYRIN, Inc.SLRN · Entity 79310 | Chief Operating Officer | May 23, 2024 | May 24, 2024 |
| Immunovant, Inc.IMVT · Entity 3632 | Chief Operating Officer | October 07, 2026 | October 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACELYRIN, Inc.
Report date May 23, 2024 · Filed May 24, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.22 · Expires 2034-05-22 | Direct | 184,042 |
Reported balance
After 2024-05-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-05-23 · Grant · Acquired 184,042 · Balance 184,042 F1: 33% of the shares subject to the option vest on December 15, 2024, 34% of the shares subject to the option vest on June 15, 2025, and the remaining 33% of the shares subject to the option vest on December 15, 2025, subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: 33% of the shares subject to the option vest on December 15, 2024, 34% of the shares subject to the option vest on June 15, 2025, and the remaining 33% of the shares subject to the option vest on December 15, 2025, subject to the Reporting Person's continued service.
Immunovant, Inc.
Report date October 07, 2026 · Filed October 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 217,060 |
Reported balance
After 2026-10-07 transaction · row 1
1 source rowRow 1 · 2026-10-07 · Sale · Disposed 2,241 · Balance 217,060 F1: On April 1, 2025, the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 4,761 of these RSUs vested on October 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.58 - $32.30 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 1, 2025, the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 4,761 of these RSUs vested on October 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.58 - $32.30 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 07, 2026 Filed Oct 9, 2026 21:04 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,241 | $32.06 | $71,846.46 |
DisclosureSEC source: 0001764013-26-000112 · wk-form4_1791579845.xml · nonDerivative · entry 1 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,060 F1 · shares: On April 1, 2025, the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 4,761 of these RSUs vested on October 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.58 - $32.30 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 20:03 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 3,056 | $44.16 | $134,952.96 |
DisclosureSEC source: 0001973838-26-000007 · wk-form4_1787342630.xml · nonDerivative · entry 1 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 219,301 F1 · shares: On November 18, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 20, 2024, of which 6,872 of these RSUs vested on August 18, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.80 - $44.37 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| July 08, 2026 Filed Jul 10, 2026 20:15 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 106 | $39.99 | $4,238.94 |
DisclosureSEC source: 0001764013-26-000083 · wk-form4_1783714509.xml · nonDerivative · entry 2 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,357 F1 · shares: On April 1, 2025, the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 4,761 of these RSUs vested on July 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.92 - $40.03 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| July 08, 2026 Filed Jul 10, 2026 20:15 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1,930 | $39.53 | $76,292.90 |
DisclosureSEC source: 0001764013-26-000083 · wk-form4_1783714509.xml · nonDerivative · entry 1 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,463 F1 · shares: On April 1, 2025, the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 4,761 of these RSUs vested on July 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.91 - $39.89 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| June 26, 2026 Filed Jun 26, 2026 23:46 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,966 | $38.95 | $115,525.70 |
DisclosureSEC source: 0001764013-26-000075 · wk-form4_1782517606.xml · nonDerivative · entry 2 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,393 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.78 - $39.13 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| June 26, 2026 Filed Jun 26, 2026 23:46 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 14,748 | $38.18 | $563,078.64 |
DisclosureSEC source: 0001764013-26-000075 · wk-form4_1782517606.xml · nonDerivative · entry 1 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227,359 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.77 - $38.56 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:03 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1,698 | $32.95 | $55,949.10 |
DisclosureSEC source: 0001764013-26-000067 · wk-form4_1779480209.xml · nonDerivative · entry 3 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 242,107 F1 · shares: On November 18, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 20, 2024, of which 6,872 of these RSUs vested on May 18, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.55 - $33.49 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:03 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1,168 | $32.15 | $37,551.20 |
DisclosureSEC source: 0001764013-26-000067 · wk-form4_1779480209.xml · nonDerivative · entry 2 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,805 F1 · shares: On November 18, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 20, 2024, of which 6,872 of these RSUs vested on May 18, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.55 - $32.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:03 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 249 | $30.41 | $7,572.09 |
DisclosureSEC source: 0001764013-26-000067 · wk-form4_1779480209.xml · nonDerivative · entry 1 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 244,973 F1 · shares: On November 18, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 20, 2024, of which 6,872 of these RSUs vested on May 18, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.32 - $31.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 08, 2026 Filed Apr 10, 2026 20:03 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 8,722 | $24.83 | $216,567.26 |
DisclosureSEC source: 0001973838-26-000004 · wk-form4_1775851435.xml · nonDerivative · entry 1 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 245,222 F1 · shares: On April 1, 2025, the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 19,045 of these RSUs vested on April 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.54 - $25.39 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 20:20 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 121,063 | $0.00 Strike: $24.61 | $0.00 |
DisclosureSEC source: 0001764013-26-000040 · wk-form4_1775766037.xml · derivative · entry 2 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,063 Underlying: Common Stock · 121,063 shares Expires 2036-04-07 F2 · derivative.exercise_date: These options were granted pursuant to the Plan. The shares underlying the options will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in thirty-six (36) successive substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 20:20 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 83,671 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-26-000040 · wk-form4_1775766037.xml · nonDerivative · entry 1 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 253,944 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in twelve (12) successive substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 21:07 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 942 | $28.90 | $27,223.80 |
DisclosureSEC source: 0001764013-26-000013 · wk-form4_1772226458.xml · nonDerivative · entry 3 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,273 F1 · shares: On November 18, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 20, 2024, of which 6,872 of these RSUs vested on February 18, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.70 - $29.13 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 21:07 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 859 | $28.16 | $24,189.44 |
DisclosureSEC source: 0001764013-26-000013 · wk-form4_1772226458.xml · nonDerivative · entry 2 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,215 F1 · shares: On November 18, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 20, 2024, of which 6,872 of these RSUs vested on February 18, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.67 - $28.61 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 21:07 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1,437 | $26.98 | $38,770.26 |
DisclosureSEC source: 0001764013-26-000013 · wk-form4_1772226458.xml · nonDerivative · entry 1 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,074 F1 · shares: On November 18, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 20, 2024, of which 6,872 of these RSUs vested on February 18, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.66 - $27.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 20, 2025 Filed Nov 21, 2025 21:24 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,375 | $23.97 | $56,928.75 |
DisclosureSEC source: 0001764013-25-000156 · wk-form4_1763760245.xml · nonDerivative · entry 2 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,511 F1 · shares: On November 18, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 20, 2024, of which 27,489 of these RSUs vested on November 18, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.93 - $24.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 20, 2025 Filed Nov 21, 2025 21:24 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 10,251 | $23.54 | $241,308.54 |
DisclosureSEC source: 0001764013-25-000156 · wk-form4_1763760245.xml · nonDerivative · entry 1 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,886 F1 · shares: On November 18, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 20, 2024, of which 27,489 of these RSUs vested on November 18, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.93 - $23.91 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:53 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 107,297 | $0.00 Strike: $15.20 | $0.00 |
DisclosureSEC source: 0001764013-25-000057 · wk-form4_1743713606.xml · derivative · entry 2 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,297 Underlying: Common Stock · 107,297 shares Expires 2035-04-01 F2 · derivative.exercise_date: The shares underlying the options will vest as to 25% of the shares on April 1, 2026 and the remainder will vest in 36 substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:53 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 76,181 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-25-000057 · wk-form4_1743713606.xml · nonDerivative · entry 1 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,137 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on April 1, 2026, and the remainder will vest in substantially equal installments on a quarterly basis over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 22:15 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 137,446 | $0.00 Strike: $25.51 | $0.00 |
DisclosureSEC source: 0001764013-24-000188 · wk-form4_1732140934.xml · derivative · entry 2 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,446 Underlying: Common Stock · 137,446 shares Expires 2034-11-18 F2 · derivative.exercise_date: This option was granted pursuant to the Issuer's 2019 Equity Incentive Plan. The shares underlying the option will vest as to 25% of the shares on November 18, 2025, and the remainder will vest in 12 successive substantially equal quarterly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 22:15 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 109,956 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-24-000188 · wk-form4_1732140934.xml · nonDerivative · entry 1 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,956 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on November 18, 2025, and the remainder will vest in 12 successive substantially equal quarterly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| May 23, 2024 Filed May 24, 2024 23:06 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | GrantEmployee Stock Option (right to buy) · Derivative | 184,042 | $0.00 Strike: $4.22 | $0.00 |
DisclosureSEC source: 0001962918-24-000067 · wk-form4_1716591959.xml · derivative · entry 1 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,042 Underlying: Common Stock · 184,042 shares Expires 2034-05-22 F1 · derivative.exercise_date: 33% of the shares subject to the option vest on December 15, 2024, 34% of the shares subject to the option vest on June 15, 2025, and the remaining 33% of the shares subject to the option vest on December 15, 2025, subject to the Reporting Person's continued service. Read SEC document |
| May 15, 2024 Filed May 17, 2024 23:12 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | Tax withholdingCommon Stock | 10,298 | $4.47 | $46,032.06 |
DisclosureSEC source: 0001962918-24-000063 · wk-form4_1715987559.xml · nonDerivative · entry 1 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,286 F1 · shares: Represents the total number of shares withheld to settle the Reporting Person's tax liability for the Restricted Stock Units that vested on May 15, 2024. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 23:31 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | GrantEmployee Stock Option (right to buy) · Derivative | 494,297 | $0.00 Strike: $7.68 | $0.00 |
DisclosureSEC source: 0001962918-24-000006 · wk-form4_1705015852.xml · derivative · entry 1 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 494,297 Underlying: Common Stock · 494,297 shares Expires 2034-01-08 F1 · derivative.exercise_date: 1/4 of the shares subject to the option vest on January 9, 2025, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 22:50 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | GrantCommon Stock | 140,584 | $0.00 | $0.00 |
DisclosureSEC source: 0001962918-23-000022 · wk-form4_1692399025.xml · nonDerivative · entry 1 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,584 F1 · shares: Represents Restricted Stock Units (RSUs). 1/4 of the RSUs will vest on May 15, 2024 and the remaining RSUs will vest in three equal annual installments thereafter, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| May 09, 2023 Filed May 12, 2023 00:56 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | OtherEmployee Stock Option (right to buy) · Derivative | 232,436 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028868 · doc4.xml · derivative · entry 6 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,436 Underlying: Common Stock · 232,436 shares Expires 2033-05-03 F1 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vest on May 4, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. F1 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. Read SEC document |
| May 09, 2023 Filed May 12, 2023 00:56 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | OtherEmployee Stock Option (right to buy) · Derivative | 232,436 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028868 · doc4.xml · derivative · entry 5 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 232,436 shares Expires 2033-05-03 F1 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vest on May 4, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. F1 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. Read SEC document |
| May 09, 2023 Filed May 12, 2023 00:56 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | OtherEmployee Stock Option (right to buy) · Derivative | 187,988 | $0.00 Strike: $5.88 | $0.00 |
DisclosureSEC source: 0001209191-23-028868 · doc4.xml · derivative · entry 4 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,988 Underlying: Common Stock · 187,988 shares Expires 2032-11-20 F1 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. F3 · derivative.exercise_date: 1/4 of the shares subject to the option vest on November 17, 2023, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service. F1 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. Read SEC document |
| May 09, 2023 Filed May 12, 2023 00:56 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | OtherEmployee Stock Option (right to buy) · Derivative | 187,988 | $0.00 Strike: $5.88 | $0.00 |
DisclosureSEC source: 0001209191-23-028868 · doc4.xml · derivative · entry 3 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 187,988 shares Expires 2032-11-20 F1 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. F3 · derivative.exercise_date: 1/4 of the shares subject to the option vest on November 17, 2023, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service. F1 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. Read SEC document |
| May 09, 2023 Filed May 12, 2023 00:56 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | OtherEmployee Stock Option (right to buy) · Derivative | 330,181 | $0.00 Strike: $4.04 | $0.00 |
DisclosureSEC source: 0001209191-23-028868 · doc4.xml · derivative · entry 2 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 330,181 Underlying: Common Stock · 330,181 shares Expires 2032-01-19 F1 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. F2 · derivative.exercise_date: 1/4 of the shares subject to the option vested on November 8, 2022 and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. F1 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. Read SEC document |
| May 09, 2023 Filed May 12, 2023 00:56 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | OtherEmployee Stock Option (right to buy) · Derivative | 330,181 | $0.00 Strike: $4.04 | $0.00 |
DisclosureSEC source: 0001209191-23-028868 · doc4.xml · derivative · entry 1 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 330,181 shares Expires 2032-01-19 F1 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. F2 · derivative.exercise_date: 1/4 of the shares subject to the option vested on November 8, 2022 and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. F1 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. Read SEC document |
| May 04, 2023 Filed May 5, 2023 00:03 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | GrantEmployee Stock Option (right to buy) · Derivative | 232,436 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-23-027518 · doc4.xml · derivative · entry 1 Gloria Melanie · CIK 0001973838 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,436 Underlying: Class A Common Stock · 232,436 shares Expires 2033-05-03 F1 · derivative.exercise_date: 1/4 of the shares subject to the option vest on May 4, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. F2 · derivative.underlying: Each share of Class A Common Stock shall be reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.